Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 5/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 7/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL615063 | 0.86 | L3MBTL1 (0.40) | PIM1METMAPK1CYP11B1CYP11B2 | |
| SCHEMBL614851 | 0.80 | L3MBTL1 (0.39) | MAPTCYP11B1 | |
| SCHEMBL615038 | 0.78 | FGFR1 (0.38) | METMAPTCYP11B1CYP11B2CHRM1 | |
| SCHEMBL626765 | 0.76 | ELANE (0.40) | METMAPTCYP11B1CYP11B2CHRM1 | |
| SCHEMBL7906411 | 0.67 | FGFR1 (0.47) | METCYP11B1CYP11B2CHRM1HDAC1 | |
| SCHEMBL14875371 | 0.66 | PDE4A (0.38) | MAPTMAPK1CHRM1 | |
| SCHEMBL15107493 | 0.66 | CHRM1 (0.38) | METCYP11B1CYP11B2CHRM1HDAC1 | |
| SCHEMBL24205908 | 0.66 | L3MBTL1 (0.44) | MET | |
| SCHEMBL615418 | 0.65 | CHRM1 (0.41) | CHRM1AURKAAURKB | |
| SCHEMBL615419 | 0.65 | CHRM1 (0.41) | CHRM1AURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421366-B1 | HETEROCYCLIC FUSED CINNOLINE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8293744-B2 | Heterocyclic fused cinnoline M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20120040978-A1 | Heterocyclic Fused Cinnoline M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME CORP. (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040978-A1 | Heterocyclic Fused Cinnoline M1 Receptor Positive Allosteric Modulators | CHRM1, CNR1, CHRNA7 | PIM1 2954/4885PIM3 3631/4885PIM2 3812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.